Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

1.

Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach.

Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P.

Neurology. 2010 Jul 27;75(4):302-9. doi: 10.1212/WNL.0b013e3181ea15aa. Epub 2010 Jun 23.

PMID:
20574036
[PubMed - indexed for MEDLINE]
2.

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P.

Ann Neurol. 2009 Mar;65(3):268-75. doi: 10.1002/ana.21606.

PMID:
19334061
[PubMed - indexed for MEDLINE]
3.

Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach: measuring disability in relapsing-remitting MS.

Ebers GC, Daumer M, Scalfari A.

Neurology. 2011 Mar 15;76(11):1025; author reply 1025-6. doi: 10.1212/WNL.0b013e31820a9674. No abstract available.

PMID:
21403116
[PubMed - indexed for MEDLINE]
4.

Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.

Sormani MP, Li DK, Bruzzi P, Stubinski B, Cornelisse P, Rocak S, De Stefano N.

Neurology. 2011 Nov 1;77(18):1684-90. doi: 10.1212/WNL.0b013e31823648b9. Epub 2011 Oct 5.

PMID:
21975200
[PubMed - indexed for MEDLINE]
5.
6.

Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.

Rudick RA, Fisher E, Lee JC, Duda JT, Simon J.

Mult Scler. 2000 Dec;6(6):365-72.

PMID:
11212130
[PubMed - indexed for MEDLINE]
7.

A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.

Calabrese M, Rocca MA, Atzori M, Mattisi I, Favaretto A, Perini P, Gallo P, Filippi M.

Ann Neurol. 2010 Mar;67(3):376-83. doi: 10.1002/ana.21906.

PMID:
20373349
[PubMed - indexed for MEDLINE]
8.

Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.

Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.

Mult Scler. 2008 May;14(4):479-84. doi: 10.1177/1352458507085555.

PMID:
18562504
[PubMed - indexed for MEDLINE]
9.

The incomplete nature of multiple sclerosis relapse resolution.

Lublin FD.

J Neurol Sci. 2007 May 15;256 Suppl 1:S14-8. Epub 2007 Mar 2. Review.

PMID:
17337274
[PubMed - indexed for MEDLINE]
10.

Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.

Debouverie M, Vandenberghe N, Morrissey SP, Anxionnat R, Pittion-Vouyovitch S, Vespignani H, Edan G.

Mult Scler. 2004 Aug;10(4):407-12.

PMID:
15327038
[PubMed - indexed for MEDLINE]
11.

Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.

Young PJ, Lederer C, Eder K, Daumer M, Neiss A, Polman C, Kappos L; Sylvia Lawry Centre for Multiple Sclerosis Research.

Neurology. 2006 Sep 12;67(5):804-8.

PMID:
16966541
[PubMed - indexed for MEDLINE]
12.

Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large scale, short-term follow-up study.

Mesaros S, Rocca MA, Sormani MP, Charil A, Comi G, Filippi M.

J Neurol. 2008 Sep;255(9):1378-83. doi: 10.1007/s00415-008-0924-5. Epub 2008 Jul 3.

PMID:
18584233
[PubMed - indexed for MEDLINE]
13.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
[PubMed - indexed for MEDLINE]
14.

Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years.

Turner B, Lin X, Calmon G, Roberts N, Blumhardt LD.

Mult Scler. 2003 Feb;9(1):21-7.

PMID:
12617263
[PubMed - indexed for MEDLINE]
15.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
[PubMed - indexed for MEDLINE]
16.

Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.

Brettschneider J, Petzold A, Junker A, Tumani H.

Mult Scler. 2006 Apr;12(2):143-8.

PMID:
16629417
[PubMed - indexed for MEDLINE]
17.

Assessing disability progression with the Multiple Sclerosis Functional Composite.

Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.

Mult Scler. 2009 Aug;15(8):984-97. doi: 10.1177/1352458509106212.

PMID:
19667023
[PubMed - indexed for MEDLINE]
18.

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.

Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, Mass MK, Miller D, Simonian NA.

Neurology. 2001 May 22;56(10):1324-30.

PMID:
11376182
[PubMed - indexed for MEDLINE]
19.

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients.

Fisher E, Rudick RA, Cutter G, Baier M, Miller D, Weinstock-Guttman B, Mass MK, Dougherty DS, Simonian NA.

Mult Scler. 2000 Dec;6(6):373-7.

PMID:
11212131
[PubMed - indexed for MEDLINE]
20.

Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis.

Jung P, Beyerle A, Ziemann U.

Mult Scler. 2008 May;14(4):553-6. doi: 10.1177/1352458507085758.

PMID:
18562509
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk